| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| Tau (D1M9X) XP® Rabbit mAb | 46687 | 20 µl | 50-80 kDa | Rabbit IgG |
| Phospho-Tau (Ser214) (D1Q2X) Rabbit mAb | 77348 | 20 µl | 50-80 kDa | Rabbit IgG |
| Phospho-Tau (Thr217) (E9Y4S) Rabbit mAb | 51625 | 20 µl | 50-80 kDa | Rabbit IgG |
| Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb | 4511 | 20 µl | 43 kDa | Rabbit IgG |
| Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb | 4668 | 20 µl | 46, 54 kDa | Rabbit IgG |
| Phospho-p70 S6 Kinase (Thr389) (D5U1O) Rabbit mAb | 97596 | 20 µl | 70, 85 kDa | Rabbit IgG |
| p38 MAPK (D13E1) XP® Rabbit mAb | 8690 | 20 µl | 40 kDa | Rabbit IgG |
| p70 S6 Kinase (E8K6T) XP® Rabbit mAb | 34475 | 20 µl | 70, 85 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Phospho-Tau (Ser214/T217) Signaling Antibody Sampler Kit provides an economical means of detecting the signaling cascade leading to tau phosphorylation at Ser214 and Thr217, using phospho-specific and control antibodies. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Storage
Background
Tau is a heterogeneous microtubule-associated protein that promotes and stabilizes microtubule assembly, especially in axons. Six isoforms with different amino-terminal inserts and different numbers of tandem repeats near the carboxy terminus have been identified, and tau is hyperphosphorylated at approximately 25 sites by Erk, glycogen synthase kinase-3 (GSK-3), and CDK5 (1,2). Phosphorylation decreases the ability of tau to bind to microtubules. Neurofibrillary tangles are a major hallmark of Alzheimer's disease (AD); these tangles are bundles of paired helical filaments (PHFs) composed of hyperphosphorylated tau. Furthermore, research studies have shown that inclusions of tau are found in a number of other neurodegenerative diseases, collectively known as tauopathies (1,3).
Numerous kinases, including p38 MAPK, JNK, CDK5, GSK3β, and SGK1, have been shown to phosphorylate tau at Ser214, which is found in AD and dementia with Lewy bodies (4-9). p38 MAPK participates in a signaling cascade controlling cellular responses to cytokines and stress and is activated by phosphorylation at Thr180 and Tyr182, allowing for downstream tau Ser214 phosphorylation (10-13). Another kinase that phosphorylates the Ser214 site on tau is the stress-activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK). SAPK/JNK is preferentially activated by a variety of environmental stresses, including UV and gamma radiation, ceramides, inflammatory cytokines, and, in some instances, growth factors and GPCR agonists, which lead to phosphorylation of Thr183 and Tyr185 (14-19).
Tau phosphorylation at Thr217 has been identified as a highly specific biomarker of AD. Phosphorylated tau at Thr217 can be detected in cerebrospinal fluid in both preclinical and advanced stages of AD and has been shown to successfully differentiate between AD and non-AD neurodegenerative diseases (20,21). One kinase identified to phosphorylate the Thr217 site on tau is p70 S6 kinase (S6K1). S6K1 is a mitogen activated Ser/Thr protein kinase that is required for cell growth and G1 cell cycle progression (22,23). Phosphorylation of Thr389 most closely correlates with S6K1 activity in vivo (24).
- Johnson, G.V. and Stoothoff, W.H. (2004) J Cell Sci 117, 5721-9.
- Hanger, D.P. et al. (1998) J Neurochem 71, 2465-76.
- Bramblett, G.T. et al. (1993) Neuron 10, 1089-99.
- Illenberger, S. et al. (1998) Mol Biol Cell 9, 1495-512.
- Götz, J. et al. (2001) Science 293, 1491-5.
- Yang, Y.C. et al. (2006) Mol Cell Biol 26, 8357-70.
- Liu, F. et al. (2006) FEBS Lett 580, 6269-74.
- Zhu, B. et al. (2010) Am J Physiol Lung Cell Mol Physiol 299, L493-501.
- Duka, V. et al. (2013) PLoS One 8, e75025.
- Rouse, J. et al. (1994) Cell 78, 1027-37.
- Han, J. et al. (1994) Science 265, 808-11.
- Lee, J.C. et al. Nature 372, 739-46.
- Freshney, N.W. et al. (1994) Cell 78, 1039-49.
- Davis, R.J. (1999) Biochem Soc Symp 64, 1-12.
- Ichijo, H. (1999) Oncogene 18, 6087-93.
- Kyriakis, J.M. and Avruch, J. (2001) Physiol Rev 81, 807-69.
- Kyriakis, J.M. (1999) J Biol Chem 274, 5259-62.
- Leppä, S. and Bohmann, D. (1999) Oncogene 18, 6158-62.
- Whitmarsh, A.J. and Davis, R.J. (1998) Trends Biochem Sci 23, 481-5.
- Barthélemy, N.R. et al. (2020) Alzheimers Res Ther 12, 26.
- Janelidze, S. et al. (2020) Nat Commun 11, 1683.
- Pullen, N. and Thomas, G. (1997) FEBS Lett 410, 78-82.
- Dufner, A. and Thomas, G. (1999) Exp Cell Res 253, 100-9.
- Weng, Q.P. et al. (1998) J Biol Chem 273, 16621-9.
Background References
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
